
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharma is currently facing challenges with pricing for its flagship product, Baqsimi, leading to disappointing financial results. Their future success will depend on their ability to develop and bring to market new generic and proprietary pharmaceutical products, which can be a costly and risky process.
Bears say
Amphastar Pharma is expected to see continued pressure on the pricing of Baqsimi due to factors such as higher rebates and discounts, resulting in margin erosion. The company's estimates do not reflect any significant recovery in net selling price in 2027 and beyond, and there are also risks from competition in the generic epinephrine and glucagon market. The company's significant stock ownership by two directors may also lead to potential conflicts of interest and could potentially influence corporate decisions.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares